Glioblastoma (GBM) is one of the most aggressive and challenging forms of brain cancer, with limited treatment options available today. At Plus Therapeutics (NASDAQ: PSTV), we are committed to developing new therapies that can bring hope to patients and their families.
Recently, Andrew Brenner, M.D., Ph.D., one of the Principal Investigators for our RESPECT-GBM Phase 2 clinical trial, spoke with KSAT News in San Antonio about glioblastoma and why this trial represents a promising new option for patients.
Watch the interview and read the KSAT article here.
What Is Glioblastoma (GBM)?
Glioblastoma is the most common and aggressive primary brain tumor in adults. Standard treatments such as surgery, radiation, and chemotherapy often provide only temporary benefit, and recurrence is common. That is why innovative research and clinical trials are critical in the search for more effective therapies.
About the RESPECT-GBM Clinical Trial
The RESPECT-GBM trial is a Phase 2 clinical study evaluating a novel radiotherapeutic approach for patients with recurrent glioblastoma. The goal of the trial is to improve outcomes while minimizing side effects, offering patients new hope where treatment options are limited.
This study is being conducted in collaboration with UT Health San Antonio and the Mays Cancer Center at UT Health San Antonio, with Dr. Brenner serving as a lead investigator.
How Patients Can Participate
The RESPECT-GBM trial is currently recruiting eligible patients. If you or someone you know has been diagnosed with recurrent glioblastoma, you may qualify to participate.
Learn more and see eligibility criteria here: respect-trials.com/gbm
Or email our team directly at: respect@plustherapeutics.com
Moving Brain Cancer Research Forward
Every clinical trial represents a step toward more effective therapies for glioblastoma and other brain cancers. At Plus Therapeutics, we remain committed to innovation, collaboration, and patient-centered care.
To stay updated on our clinical programs and progress, follow us on LinkedIn and visit our website.
#Glioblastoma #GBM #BrainCancer #ClinicalTrials #CancerResearch #NeuroOncology #GBMTreatment #BrainTumorResearch #CancerInnovation #PlusTherapeutics #SanAntonioResearch #UTHealthSanAntonio
Recent Comments